Clinical Trial

Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

Study acronym: CIRCPAC
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-27.
Trial Details
NCT Number NCT05788744
Lead Sponsor Copenhagen University Hospital at Herlev
Collaborators: Aarhus University Hospital, University of Copenhagen, Odense University Hospital
Conditions Resectable Pancreatic Cancer
Enrollment 1,000 participants
Start Date 2023-01-01
Primary Completion 2029-01 (estimated)
Study Completion 2032-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-27